These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 34408290)

  • 1. Correction: Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019).
    Pfaller MA; Carvalhaes CG; Rhomberg P; Messer SA; Castanheira M
    J Antibiot (Tokyo); 2022 Feb; 75(2):123. PubMed ID: 34408290
    [No Abstract]   [Full Text] [Related]  

  • 2. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
    Pfaller MA; Messer SA; Jones RN; Castanheira M
    J Antibiot (Tokyo); 2015 Sep; 68(9):556-61. PubMed ID: 25899126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.
    Messer SA; Carvalhaes CG; Castanheira M; Pfaller MA
    Diagn Microbiol Infect Dis; 2020 May; 97(1):115007. PubMed ID: 32081523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN;
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.
    Pfaller MA; Messer SA; Boyken L; Tendolkar S; Hollis RJ; Diekema DJ
    J Clin Microbiol; 2004 Jul; 42(7):3142-6. PubMed ID: 15243073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global view of antimicrobial resistance. Findings of the SENTRY Antimicrobial Surveillance Program, 1997-1999.
    Pfaller MA; Jones RN
    Postgrad Med; 2001 Feb; 109(2 Suppl):10-21. PubMed ID: 19667553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Antimicrobial Surveillance Program, 1998-1999.
    Turnidge J; Bell J; Biedenbach DJ; Jones RN
    Int J Antimicrob Agents; 2002 Jul; 20(1):10-7. PubMed ID: 12127706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
    Bell JM; Turnidge JD; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):315-8. PubMed ID: 12151193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).
    Castanheira M; Messer SA; Rhomberg PR; Pfaller MA
    Diagn Microbiol Infect Dis; 2016 Jun; 85(2):200-4. PubMed ID: 27061369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
    Mutnick AH; Biedenbach DJ; Turnidge JD; Jones RN
    Diagn Microbiol Infect Dis; 2002 May; 43(1):65-73. PubMed ID: 12052631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Nagy E; Dobiasova S; Rinaldi M; Barton R; Veselov A;
    J Clin Microbiol; 2008 Feb; 46(2):515-21. PubMed ID: 18077633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.
    Pfaller MA; Carvalhaes CG; Messer SA; Rhomberg PR; Castanheira M
    Diagn Microbiol Infect Dis; 2021 Nov; 101(3):115473. PubMed ID: 34352433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
    Pfaller MA; Castanheira M; Messer SA; Jones RN
    Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Pfaller MA; Huband MD; Flamm RK; Bien PA; Castanheira M
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunistic fungal infections in the Asia-Pacific region.
    Slavin MA; Chakrabarti A
    Med Mycol; 2012 Jan; 50(1):18-25. PubMed ID: 21905945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756.
    Bell JM; Turnidge JD; Jones RN;
    Int J Antimicrob Agents; 2002 Feb; 19(2):125-32. PubMed ID: 11850165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.
    Christiansen KJ; Bell JM; Turnidge JD; Jones RN
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2049-55. PubMed ID: 15155198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program.
    Bell JM; Chitsaz M; Turnidge JD; Barton M; Walters LJ; Jones RN
    J Clin Microbiol; 2007 May; 45(5):1478-82. PubMed ID: 17344367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.